MedTrace Logo

Serum Opiorphin Level After Intraoperative Intravenous Lidocaine Infusion

NCT03502395 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2018-04-19

No results posted yet for this study

Summary

A prospective, double blinded and randomized study included women with breast cancer and underwent mastectomy, and randomly allocated into two groups of equal size. Lidocaine group and control group.

Conditions

  • Cancer, Breast

Interventions

DRUG

Lidocaine

): Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure).

DRUG

Normal saline

A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Abdelrady S Ibrahim, M.D. · Assiut University faculty of medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-04
Primary Completion
2018-01-21
Completion
2018-02-13

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03502395 on ClinicalTrials.gov